Literature DB >> 21078947

High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B.

François Chappuis, Emilie Alirol, Dagemlidet T Worku, Yolanda Mueller, Koert Ritmeijer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21078947      PMCID： PMC3019666          DOI： 10.1128/AAC.01298-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  Natural history of a visceral leishmaniasis outbreak in highland Ethiopia.

Authors:  Mercè Herrero; Giannos Orfanos; Daniel Argaw; Abate Mulugeta; Pilar Aparicio; Fernando Parreño; Oscar Bernal; Daniel Rubens; Jaime Pedraza; Maria Angeles Lima; Laurence Flevaud; Pedro Pablo Palma; Seife Bashaye; Jorge Alvar; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2009-09       Impact factor: 2.345

2.  Visceral leishmaniasis and HIV in Tigray, Ethiopia.

Authors:  Suzi Lyons; Hans Veeken; Jean Long
Journal:  Trop Med Int Health       Date:  2003-08       Impact factor: 2.622

3.  Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.

Authors:  Ana Lúcia Lyrio de Oliveira; Yvone Maia Brustoloni; Thiago Dias Fernandes; Maria Elizabeth Cavalheiros Dorval; Rivaldo Venâncio da Cunha; Márcio Neves Bóia
Journal:  Trop Doct       Date:  2009-07       Impact factor: 0.731

4.  Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources.

Authors:  J Seaman; A J Mercer; H E Sondorp; B L Herwaldt
Journal:  Ann Intern Med       Date:  1996-04-01       Impact factor: 25.391

5.  Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda.

Authors:  Yolanda Mueller; Dawson B Mbulamberi; Peter Odermatt; Axel Hoffmann; Louis Loutan; François Chappuis
Journal:  Trop Med Int Health       Date:  2009-06-22       Impact factor: 2.622

6.  Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.

Authors:  Simon Collin; Robert Davidson; Koert Ritmeijer; Kees Keus; Yosef Melaku; Sammy Kipngetich; Clive Davies
Journal:  Clin Infect Dis       Date:  2004-02-12       Impact factor: 9.079
  6 in total
  11 in total

1.  VOSalophen: a vanadium complex with a stilbene derivative-induction of apoptosis, autophagy, and efficiency in experimental cutaneous leishmaniasis.

Authors:  Patrícia de A Machado; Jessica O F Moraes; Gustavo S G Carvalho; Wallace P Lima; Gilson C Macedo; Elizandra A Britta; Celso V Nakamura; Adilson D da Silva; Alexandre Cuin; Elaine S Coimbra
Journal:  J Biol Inorg Chem       Date:  2017-06-08       Impact factor: 3.358

Review 2.  Leishmaniasis: new insights from an old and neglected disease.

Authors:  S Antinori; L Schifanella; M Corbellino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

3.  Ending neglect of older people in the response to humanitarian emergencies.

Authors:  Unni Karunakara; Frances Stevenson
Journal:  PLoS Med       Date:  2012-12-18       Impact factor: 11.069

Review 4.  Liposomal amphotericin B as a treatment for human leishmaniasis.

Authors:  Manica Balasegaram; Koert Ritmeijer; Maria Angeles Lima; Sakib Burza; Gemma Ortiz Genovese; Barbara Milani; Sara Gaspani; Julien Potet; François Chappuis
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-20       Impact factor: 4.191

5.  Cell death and ultrastructural alterations in Leishmania amazonensis caused by new compound 4-Nitrobenzaldehyde thiosemicarbazone derived from S-limonene.

Authors:  Elizandra Aparecida Britta; Débora Botura Scariot; Hugo Falzirolli; Tânia Ueda-Nakamura; Cleuza Conceição Silva; Benedito Prado Dias Filho; Redouane Borsali; Celso Vataru Nakamura
Journal:  BMC Microbiol       Date:  2014-09-26       Impact factor: 3.605

6.  Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia.

Authors:  Charles Abongomera; Koert Ritmeijer; Florian Vogt; Jozefien Buyze; Zelalem Mekonnen; Henok Admassu; Robert Colebunders; Rezika Mohammed; Lutgarde Lynen; Ermias Diro; Johan van Griensven
Journal:  PLoS One       Date:  2017-06-05       Impact factor: 3.240

7.  The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.

Authors:  Charles Abongomera; Ermias Diro; Alan de Lima Pereira; Jozefien Buyze; Kolja Stille; Fareed Ahmed; Johan van Griensven; Koert Ritmeijer
Journal:  PLoS Negl Trop Dis       Date:  2018-05-25

8.  Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study.

Authors:  Temmy Sunyoto; Julien Potet; Margriet den Boer; Koert Ritmeijer; Jose A R Postigo; Raffaella Ravinetto; Fabiana Alves; Albert Picado; Marleen Boelaert
Journal:  BMJ Open       Date:  2019-05-30       Impact factor: 2.692

9.  A clinical severity scoring system for visceral leishmaniasis in immunocompetent patients in South Sudan.

Authors:  Suzette S Kämink; Simon M Collin; Tim Harrison; Francis Gatluak; Abdul Wasay Mullahzada; Koert Ritmeijer
Journal:  PLoS Negl Trop Dis       Date:  2017-10-02

10.  Acyclic Sesquiterpenes from the Fruit Pericarp of Sapindus saponaria Induce Ultrastructural Alterations and Cell Death in Leishmania amazonensis.

Authors:  Amanda Louzano Moreira; Débora Botura Scariot; Bruna Luíza Pelegrini; Greisiele Lorena Pessini; Tânia Ueda-Nakamura; Celso Vataru Nakamura; Izabel Cristina Piloto Ferreira
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-22       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.